Trial Profile
A Multinational, Multicenter, Open-label, Randomized Controlled Trial to Investigate the Effectiveness of Tenofovir Alafenamide in Reducing Clinical Events in Chronic Hepatitis B Patients Beyond Treatment Indications by Current Guidelines
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Acronyms ATTENTION
- 19 Dec 2022 Planned End Date changed from 31 Dec 2026 to 31 Dec 2031.
- 19 Dec 2022 Planned primary completion date changed from 31 Dec 2026 to 31 Dec 2031.
- 08 Nov 2022 Interim results (n=482) reporting preliminary data presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases